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Stroke is defined as a sudden neurological deficit caused by impairment in blood flow to the brain. The normal cerebral blood flow is 55 ml/100 g of brain tissue/min. [1] . [2] . These [8] .
During vascular ischemia there is secondary lack of oxygen and glucose, which causes changes in the intracellular metabolism and finally neuronal death. The critical level of cerebral ischemia is set at the values of 23 ml/100 g/min. In the case of rapid reperfusion up to the normal values, the functional damage is reversible. When the cerebral blood flow drops below the values of 12 ml/100 g/min. the ischemic cascade is rapidly initiated and an infarction is caused. The peri-infarct area of potentially salvageable tissue is known as the ischemic penumbra. In focal cerebral ischemia of animal models infarct size correlates with the number of periinfarct spreading depression like depolarizations
Despite encouraging data from experimental animal models demonstrating large reduction in pathological infarct volume in focal and global ischemia [9] , all clinical trials of neuroprotective therapies have to date been consistently unsuccessful [7, 10] . Some neuroprotective agents have shown beneficial effect only on post hoc analysis [8] . The only efficacious therapies so far for acute ischemic stroke have been the ones that restore perfusion. Some arguments have been suggested to explain why neuroprotection works in pre-clinical experimental models but not in human beings [6] . One possible explanation for this striking discrepancy maybe the time window for the administration of the agent [10, 11] [15] .
Maybe the most significant concern is that animal studies focused on the protection of the grey matter from the tissue damage caused by the ischemic cascade with uncertain relevance to glia or white matter. However, the clinical trials also included a high proportion of patients with sub-cortical strokes and diffused white matter damage [6, 10] . In addition, the rodent brain has a higher grey to white matter ratio which may put in question the appropriateness of the experimental models [19] . NMDA antagonists, for instance, influence neuronal cell body survival [8, 15] but probably have no effect on white matter injury. The same is true regarding the role of glutamate in cortical infarct but not in lacunar stroke.
Another matter that needs to be addressed is whether the phase 3 trials have been too small to have a statistical power to detect effects that maybe clinically meaningful. Samsa et al. [20] [24] .
